Catalog No.
Product Name
Application
Product Information
Citations
-
HIV-1 Protease Inhibitor
Hinnuliquinone is a dimeric non-peptide inhibitor of HIV-1 protease, characterized by its C2-symmetry. Isolated from the fungus Nodulisphorium hinnuleum, this bis-indolyl-2,5-dihydroxybenzoquinone is notable for its potent antiviral activity against HIV-1. It serves as a valuable tool in research applications focused on HIV treatment and protease inhibition studies. -
HIV-1 Inhibitor
HIV-1 inhibitor-19 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1. It effectively inhibits mutant strains, demonstrating EC50 values of 7.3 nM for L100I, 9.2 nM for K103N, and 21.0 nM for V106A/F227L variants. This compound is valuable for research applications aimed at understanding HIV resistance mechanisms and developing targeted antiviral therapies. -
HIV-1 Integrase Inhibitor
Kuwanon L is an inhibitor of HIV-1 integrase that effectively disrupts the interaction between HIV-1 integrase and LEDGF/p75, demonstrating IC50 values of 42 µM for LEDGF-dependent and 34 µM for LEDGF-independent integrase activity. With an IC50 of 22 µM for the integrase-LEDGF/p75 interaction, Kuwanon L also inhibits HIV-1 replication in immune cells. This compound is valuable for research focused on HIV-1 infection and the mechanisms underlying viral integration. -
HIV-1 Inhibitor
HIV-1 Inhibitor-50 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that specifically targets HIV-1 reverse transcriptase with an IC50 of 50 nM. This compound exhibits notable antiviral activity, demonstrating EC50 values between 2.22 and 53.3 nM against the HIV-1 IIIB strain and various mutant strains. It is valuable for research applications focused on HIV-1 mechanisms and the development of antiviral therapeutics. -
HIV Inhibitor
HIV Capsid Modulator 1 is a potent inhibitor targeting the HIV capsid protein. As a quinazolin-4-one-bearing phenylalanine derivative, it exhibits significant antiviral activity against both HIV-1 and HIV-2. This compound is primarily utilized in research applications aimed at understanding HIV replication and developing therapeutic strategies for HIV infection. -
HIV-1 Reverse Transcriptase Inhibitor
HI-280 is an HIV-1 reverse transcriptase inhibitor that disrupts the replication cycle of the virus. Its primary mechanism involves targeting the reverse transcriptase enzyme, critical for the transcription of viral RNA into DNA. HI-280 holds potential for research applications focused on the mechanisms of HIV infection and the development of antiretroviral therapies. -
HIV Inhibitor
Cyclotriazadisulfonamide hydrochloride is a selective CD4-targeted inhibitor that effectively blocks HIV entry and replication, specifically against HIV-1. By downregulating CD4 receptor expression on cell surfaces, it significantly impedes HIV transmission. This compound exhibits inhibitory activity against HIV-1 (NL4.3) and SIV (mac251) and demonstrates enhanced efficacy in combination with cellulose acetate (CAP). Additionally, it can be incorporated into microbial gel formulations to sustain CD4 downregulation and antiviral effects, marking it as a broad-spectrum agent against HIV. -
HIV Protease Inhibitor
P-1946 is a potent HIV protease inhibitor demonstrated to have a human HIV-1 protease Ki of 2.600 nM. It exhibits strong and selective in vitro antiviral activity, remaining effective against HIV isolates that have developed resistance to existing protease inhibitors. P-1946 is suitable for research applications focused on human immunodeficiency virus type 1 (HIV-1) infection. -
Anti-HIV Agent
Peritassine A is an alkaloid derived from Tripterygium wilfordii Hook. f. that exhibits potent anti-HIV activity. This compound has shown promise in inhibiting viral replication, making it a valuable candidate for HIV research and potential therapeutic development. Its unique mechanism of action can support studies focused on antiviral strategies and the exploration of new treatment options for HIV. -
HIV Inhibitor
HIV-IN-2 is a potent inhibitor of HIV, targeting key viral processes essential for replication. This compound demonstrates significant antiviral activity, making it valuable for research applications in understanding HIV infection and its mechanisms. HIV-IN-2 offers potential insights for therapeutic strategies aimed at combatting HIV/AIDS. -
HIV Inhibitor
Tenofovir-C3-O-C15-CF3 ammonium is an innovative HIV inhibitor designed to enhance the pharmacokinetic properties over traditional tenofovir. This compound demonstrates significantly longer half-life (t1/2) values in human liver microsomes, along with potent anti-HIV activity in vitro. Its unique structure makes it a valuable candidate for research applications focused on developing more effective therapeutic strategies against HIV. -
HIV
Zintevir is an antisense oligonucleotide that specifically targets HIV-1 integrase, inhibiting viral replication. By interfering with the integration of viral DNA into the host genome, this compound demonstrates potential in antiviral research. Its applications include the study of HIV biology and the development of novel therapeutic strategies for the management of HIV infection. -
Non-nucleoside Reverse Transcriptase Inhibitor
VRX-480773 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high specificity for HIV-1, demonstrating an EC50 of 0.14 nM against wild-type strains. This compound exhibits no inhibitory effects on HIV-2, HBV, or HCV, and does not affect human DNA polymerase α/β. Additionally, VRX-480773 maintains efficacy against Efavirenz-resistant HIV-1 variants, with EC50 values generally below 1 nM. Its unique properties make it a valuable tool for research into HIV/AIDS. -
HIV‑1 Protease Inhibitor
HIV-1-IN-88 is a potent HIV-1 protease inhibitor, demonstrating an IC50 value of 10 pM and an antiviral EC50 value of 10.4 nM. This compound retains efficacy against multidrug-resistant HIV-1 variants, including HIV-1Muta and HIV-1I50V, with EC50 values of 30.0 nM and 34.3 nM, respectively. HIV-1-IN-88 serves as a valuable tool for research aimed at understanding and combating HIV infection and resistance mechanisms. -
Non-nucleoside Reverse Transcriptase Inhibitor
HI-207 is a non-nucleoside reverse transcriptase inhibitor with demonstrated anti-HIV activity. It exhibits an IC50 value of 0.27 μM in PBMC/p24 inhibition assays, making it a potent candidate for studies investigating HIV infection mechanisms and therapeutic interventions. This compound is useful for researchers focusing on antiviral drug development and the modulation of HIV replication. -
HIV-1 Reverse Transcriptase Inhibitor
R-82150 is an HIV-1 reverse transcriptase inhibitor that functions by binding to the non-substrate binding site of the reverse transcriptase enzyme, effectively blocking the reverse transcription of viral RNA. This mechanism inhibits viral replication in HIV-1, while showing no effect on HIV-2, other RNA viruses, or DNA viruses. R-82150 is primarily utilized in research focused on understanding HIV-1 replication and therapeutic interventions. -
HIV-1 Inhibitor
CGP-75355 is a potent inhibitor of HIV-1 protease, exhibiting an IC50 of 26 nM. This bis(L-tert-leucine) derivative effectively disrupts viral replication, making it a valuable tool for studying HIV-1 protease function and for the development of antiviral therapies. Its specificity and efficacy position CGP-75355 as a critical reagent in HIV research applications. -
HIV-1 Replication Inhibitor
DQBS is an inhibitor targeting the HIV-1 Nef protein, which plays a critical role in HIV replication. By binding to Nef, DQBS effectively inhibits the Nef-dependent processes essential for viral replication. This compound is valuable for research aimed at understanding HIV pathogenesis and developing therapeutic strategies to combat HIV infection. -
HIV Inhibitor
GSK-364735 potassium is a potent HIV integrase inhibitor, targeting the integrase enzyme of human immunodeficiency virus type 1 (HIV-1) with an IC50 of 7.8 nM. This compound plays a crucial role in antiretroviral research by disrupting viral replication and integration processes. Its application extends to the development of therapeutic strategies against HIV, making it a valuable tool for researchers in the field of virology and infectious disease. -
Nucleoside Reverse Transcriptase Inhibitor
Lamivudine-13C,15N2 is a labeled impurity of Lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI). This compound effectively inhibits the reverse transcriptase activity of HIV-1 and HIV-2, as well as that of the hepatitis B virus, making it valuable in antiviral research. It is utilized in studies aiming to understand the pharmacokinetics and metabolic pathways of Lamivudine and its derivatives. -
Anti-HIV Agent
Asuptegravir is a potent inhibitor of HIV integrase, a critical enzyme for the viral replication process. This compound demonstrates significant antiviral activity against HIV in HEK293T cells, with an EC50 value of 1.08 nM. Asuptegravir is suitable for research applications focused on anti-AIDS and HIV treatment strategies. -
HIV Inhibitor
CGP 57813 is a peptidomimetic inhibitor of HIV protease, designed to interfere with viral replication. This compound exhibits potential in therapeutic applications targeting HIV infection. Its ability to be encapsulated in nanoparticles made from poly(D,L-lactic acid) and pH-sensitive methacrylic acid copolymers enhances its delivery and stability within biological systems. -
Anti-HIV-1 Agent
PB(OH)3 is an effective anti-HIV-1 agent that targets viral replication mechanisms. This compound demonstrates significant antiviral activity, making it a valuable tool for studying HIV-1 pathogenesis and the development of therapeutic strategies. Its application in antiviral research contributes to a better understanding of HIV-1 biology and potential treatment pathways. -
CCR5 Antagonist
E913 is a selective antagonist of the CCR5 receptor, effectively inhibiting the binding of macrophage inflammatory protein-1alpha (MIP-1alpha) to CCR5 with an IC50 of 0.002 μM. This compound also blocks MIP-1alpha-induced cellular Ca2+ mobilization, demonstrating an IC50 of 0.02 μM. E913 significantly suppresses the replication of both laboratory and primary R5 HIV-1 strains, including multidrug-resistant variants, with IC50 values ranging from 0.03 to 0.06 μM. This reagent is valuable for research into HIV-1 infection and related mechanisms of immune response. -
HIV-1 Inhibitor
JTK-101 is a selective inhibitor of HIV-1, primarily targeting Tat cofactors such as CDK9 and cyclin T1. By inhibiting these cofactors, JTK-101 effectively reduces HIV-1 mRNA synthesis and suppresses the transcriptional activity of the virus. This compound is valuable for research applications focused on anti-HIV therapeutic strategies and understanding HIV transcription regulation. -
HIV-1 Inhibitor
L-708906 is a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) with an IC50 value of 12 μM. This compound effectively inhibits HIV strains that are resistant to both nonnucleoside and nucleoside reverse transcriptase inhibitors. L-708906 is useful in research applications focused on the development of new therapeutic strategies for HIV treatment and resistance management. -
Anti-HIV-1 Agent
GS-7339 is a diastereomer of GS-7171 and serves as a potent anti-HIV-1 agent, exhibiting an IC50 of 0.06 μM. This compound is instrumental for research into HIV-1 infection mechanisms and potential therapeutic interventions. Its efficacy makes it a valuable tool for studies aimed at understanding HIV-1 transmission and replication. -
anti-HIV
Crotoniazide is an isonicotinic acid hydrazide derivative that exhibits anti-HIV activity with an EC50 value of 11 µg/mL. This compound targets the replication process of the virus, making it valuable for research into HIV therapeutics. Its potential utility in studying HIV pathogenesis and resistance mechanisms highlights its importance in virology research. -
HIV Inhibitor
Salaspermic acid is a triterpene acid derived from Salacia macrosperma Wight, functioning as an inhibitor of HIV reverse transcriptase. This compound demonstrates significant antiviral activity by effectively reducing HIV replication in H9 lymphocyte cells. Salaspermic acid serves as a valuable tool for research focused on HIV pathogenesis and therapeutic development. -
HIV-1 Reverse Transcriptase Inhibitor
Mesoxalate, a dicarboxylic and ketonic acid, serves as an inhibitor of HIV-1 reverse transcriptase (RT). It exerts biological activity with an IC50 value of 2.2 μM, making it a valuable tool for studying the inhibition of HIV replication. Mesoxalate is applicable in research focusing on antiviral therapies targeting retroviral enzymes. -
Anti-HIV-1 Agent
ZP7 is a potent anti-HIV-1 agent that targets the replication cycle of the virus. With an effective concentration (EC50) of 36.4 nM, ZP7 demonstrates significant antiviral activity against HIV-1. This compound is suitable for use in HIV-1 research applications, providing essential insights into viral mechanisms and potential therapeutic strategies. -
HIV-1 Inhibitor
RDEA-427 is a pyrrolopyrimidine derivative that acts as a non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1. This compound demonstrates efficacy against both wild-type and NNRTI-resistant mutant strains of HIV-1. RDEA-427 is suitable for research applications focused on HIV infection and the mechanisms of viral resistance. -
HIV-1 Reverse Transcriptase Inhibitor
L-702007 is a potent inhibitor of HIV-1 reverse transcriptase, a critical enzyme in the life cycle of the HIV virus. By obstructing viral replication, it exhibits significant antiviral activity, making it a valuable tool in HIV research. This compound is instrumental in studying the mechanisms of HIV infection and testing potential antiviral therapies. -
HIV Inhibitor
Adenallene is a nucleoside analogue that functions as an anti-HIV agent. It effectively inhibits the replication of both HIV-1 and HIV-2, demonstrating the ability to reduce cytopathic effects associated with these viruses. This compound is valuable for research focused on antiviral drug development and HIV pathogenesis studies. -
HIV-1 Inhibitor
GSK878 is a highly potent HIV-1 inhibitor that exerts its antiviral effects through the selective targeting of viral replication mechanisms. With an EC50 value of 39 pM, it demonstrates strong efficacy in suppressing HIV-1 activity. This compound is utilized in research for its potential applications in the development of long-acting therapeutic strategies for HIV treatment. -
HIV Inhibitor
HIV-IN-8 is an effective HIV inhibitor that targets the replication process of the virus. With an EC50 value of 13 μg/mL, this compound demonstrates a significant capacity to inhibit HIV replication in vitro. It is suitable for research applications focused on understanding HIV biology and evaluating antiviral strategies. -
HIV-1 IN Inhibitor
Hyrtiosal is a potent inhibitor of the N-terminal domain (NTD) of HIV-1 integrase (HIV-1 IN), exhibiting an IC50 value of 9.60-0.86 μM. By specifically binding to the Ser17, Trp19, and Lys34 residues on the NTD, Hyrtiosal effectively disrupts the interaction between HIV-1 viral DNA and integrase, thus hindering the formation of the pre-integrated complex essential for viral replication. This compound is valuable for research focused on discovering and developing novel anti-HIV therapeutics. -
HIV-1 Reverse Transcriptase Inhibitor
NNRT-IN-10 is a potent, selective non-nucleoside inhibitor of HIV-1 reverse transcriptase, demonstrating EC50 values ranging from 1.16 to 18.3 nM against HIV and its mutant strains. This compound exhibits favorable pharmacokinetic properties and safety profiles, making it suitable for research applications in studying HIV-1 and AIDS. NNRT-IN-10 represents a crucial tool for advancing antiviral research targeting HIV-1 replication. -
HIV Protease Inhibitor
BMS 186318 is a potent HIV protease inhibitor that plays a critical role in blocking viral replication by interfering with the proteolytic processing of viral polyproteins. This compound demonstrates enhanced anti-HIV efficacy when used in conjunction with reverse transcriptase inhibitors and additional protease inhibitors. BMS 186318 is ideal for applications in antiviral research, contributing to the development of effective therapeutic strategies against HIV. -
Anti-HIV Drug
Suberosol is a C31 lanostane-type triterpene with primary activity as an anti-HIV agent. It exhibits significant anti-HIV replication efficacy in H9 lymphocyte cells, demonstrating an EC50 value of 3 μg/mL. This compound is valuable for research related to HIV treatment and therapeutic development. -
HIV-1 integrase Inhibitor
MK-0536 is a potent inhibitor of HIV-1 integrase, demonstrating significant efficacy in suppressing the replication of wild-type viruses. This compound retains antiviral activity against several drug-resistant mutants, including Y143R and N155H, while exhibiting no cytotoxic effects on uninfected cells. MK-0536 operates by selectively blocking the strand transfer reaction of integrase through magnesium ion chelation at the active site, as well as interactions with viral DNA and integrase residues. This reagent is valuable for investigating the mechanisms underlying HIV infection and resistance. -
Anti-HIV Agent
SC-49483, a butanoylated ester of Miglustat, functions as an anti-HIV agent. This compound demonstrates significant bioactivity against HIV, making it a valuable tool for researchers studying HIV infection and its associated mechanisms. SC-49483 aids in the exploration of therapeutic strategies targeting viral replication and the host-virus interaction. -
HIV-1 Reverse Transcriptase Inhibitor
TSAO-T is a potent inhibitor of HIV-1 reverse transcriptase, a key enzyme in the retroviral replication cycle. By disrupting this enzyme's activity, TSAO-T effectively impedes viral replication, making it a valuable tool in HIV research. Its use can facilitate the study of HIV infection mechanisms and the development of novel therapeutic strategies. -
Non-Nucleoside Reverse Transcriptase Inhibitor
DPC 961 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that specifically targets HIV-1 reverse transcriptase. It exerts its biological activity by non-competitively inhibiting the enzymatic function of reverse transcriptase, effectively blocking viral replication. This compound is primarily utilized in research focused on AIDS and the mechanisms of HIV pathogenesis. -
Non-nucleoside Reverse Transcriptase Inhibitor
DPC 963 is an oral active non-nucleoside reverse transcriptase inhibitor that demonstrates an IC50 of 18 nM. This compound is primarily utilized in the study of HIV, providing insights into reverse transcription processes and potential therapeutic strategies. Its potent inhibitory activity makes DPC 963 a valuable tool for research in antiviral drug development and HIV pathogenesis. -
HIV-1 nucleotide reverse transcriptase Inhibitor
GS-9148 is a ribose-modified inhibitor of HIV-1 nucleotide reverse transcriptase, exhibiting an EC50 value of 10.6 µM. This compound demonstrates significant antiretroviral activity against HIV-1 strains with mutations at K65R, L74V, and M184V. GS-9148 is a valuable tool for research focused on HIV resistance mechanisms and the development of novel therapeutic strategies. -
HIV Attachment Inhibitor
BMS-663749 is an HIV attachment inhibitor that functions as a phosphonooxymethyl prodrug of BMS-488043. This compound effectively interferes with the binding of the HIV virus to host cells, thereby preventing viral entry and infection. BMS-663749 is primarily utilized in research focused on HIV biochemistry and therapeutic development strategies targeting viral attachment processes. -
HIV-1 Inhibitor
A-75925 is a selective inhibitor of the HIV-1 protease, a key enzyme in the viral replication process. By interfering with the protease activity, A-75925 effectively inhibits HIV-1 replication, making it a valuable tool in HIV research. This compound can be employed to investigate antiviral strategies and the mechanisms underlying HIV resistance. -
HIV-1 Inhibitor
N.41 is an HIV-1 inhibitor that functions by disrupting the interaction between the viral Vif protein and the host antiviral factor APOBEC3G (A3G). By protecting A3G from Vif-mediated degradation, N.41 increases cellular levels of A3G and enhances its incorporation into viral particles, resulting in reduced HIV-1 infectivity. This compound demonstrates significant antiviral activity against HIV-1 replication in peripheral blood mononuclear cells (PBMCs), with an IC50 value of 8.4 μM, highlighting its potential for research applications in HIV-1 studies and antiviral drug development. -
HIV-1 Inhibitor
NBD-10007 is a CD4 agonist that specifically targets HIV-1. It demonstrates significant anti-HIV-1 viral activity, making it a valuable reagent for studying HIV pathogenesis and testing potential therapeutic interventions. Its unique mechanism of action may provide insights into CD4 receptor modulation and immune responses in HIV infection research.
